Rosenow F, Brandt C, Bozorg A, et al. - In adults with cerebrovascular epilepsy etiology (CVEE), researchers evaluated tolerability and effectiveness of lacosamide. In these exploratory post hoc analyses, patients with CVEE have been identified based on epilepsy etiology recorded at baseline. Sixty-one individuals had CVEE (lacosamide: 27; carbamazepine-controlled release [carbamazepine-CR]: 34) in the initial monotherapy trial. Twenty patients on lacosamide (27 [79.4%] on carbamazepine-CR) reported treatment-emergent adverse events (TEAEs). Headache, dizziness, and fatigue were the most commonly TEAEs. Findings revealed that 26/30 patients with CVEE reported TEAEs (most commonly dizziness, convulsion, fatigue, headache, somnolence, and cognitive disorder) in the conversion to monotherapy trial. It was noted that 36/83 patients with CVEE reported TEAEs (most commonly fatigue and dizziness) in the observational study. In patients with CVEE, lacosamide was generally effective and well-tolerated. Data from the initial monotherapy trial suggesting greater efficacy numerically than carbamazepine-CR.